AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: DNA
Report Date: 2026-09-22
Full Report: https://amaly.io/stock/DNA

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: Ginkgo Bioworks Holdings, Inc. (DNA) operates in the biotechnology sector, developing cell programming platforms for therapeutics, food ingredients, and chemicals. While its core business activities are Shariah-compliant, the company fails financial screening criteria across major standards due to high debt (77.34%) and liquidity (92.00%) ratios exceeding thresholds. Non-permissible income is minimal at 0.99%, requiring purification. The stock is not included in any major Shariah indices, resulting in an overall non-compliant status. Investors should monitor debt reduction efforts and consider alternatives in the healthcare sector.

Primary Compliance Concerns:
- Debt Ratio: 77.34% (exceeds AAOIFI 30%, MSCI 33.33%, S&P 33% thresholds)
- Liquidity Ratio: 92.00% (exceeds all standards' 30-33% thresholds)

Purification Requirement: 0.99%
Index Inclusion: Not included in S&P Dow Jones Shariah, MSCI Islamic, FTSE Shariah, or DJIM indices.

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 77.3%
Liquidity Ratio: 92.0%
Interest Income Ratio: 0.0%
Purification Required: 0.99%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2025-12-31

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-27T12:00:00Z

---
Full interactive report: https://amaly.io/stock/DNA
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.